Is it necessary to take Neratinib after dual target treatment?

Dual-target therapy is a commonly used approach to breast cancer treatment that involves the use of trastuzumab or pertuzumab. Neratinib (Neratinib) is an oral drug that is a dual tyrosine kinase inhibitor that works by inhibiting the activity of the HER2 receptor signaling pathway. Ifpatients are considering or receiving dual-target therapy, it is recommended to consult their doctor to understand whether they need to use neratinib and related treatments at the same time.

Neratinib is often used with trastuzumab as adjuvant therapy or as a first-line option for treatment of HER2-positive breast cancer. Because neratinib and trastuzumab have different mechanisms of action on the HER2 pathway, in patients with early-stage breast cancer who completed trastuzumab-based adjuvant therapy, studies showed neratinib significantly improved the 5-year invasive disease-free survival (iDFS) rate. Neratinib has excellent tolerability and feasibility. Although the use of neratinib may have some side effects in some cases, it is important to prevent disease recurrence and improve survival rates.

NeratinibThe original drug is marketed in China as neratinib maleate tablets and is covered by Class B medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of each box of 40mg*180 tablets may be around 7,000 yuan. Generic drugs of neratinib are also sold overseas. The drug ingredients are basically the same as those of the original drug. The price of 40mg*180 tablets produced by Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to the exchange rate). For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.